O
APLM icon

OrbiMed’s Apollomics APLM Stock Holding History

OrbiMed’s Portfolio APLM Stock Details APLM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-85,655
Closed -$1.81M – 120
2024
Q2 		$1.81M Hold
85,655
– – 0.04% 107
2024
Q1 		$6.42M Hold
85,655
– – 0.12% 94
2023
Q4 		$8.27M Sell
85,655
-94,281
-52% -$11.6M 0.17% 81
2023
Q3 		$67.4M Buy
179,936
+173,310
+2,616% +$84.7M 1.43% 23
2023
Q2 		$3.8M Hold
6,626
– – 0.07% 108
2023
Q1 		$16M Buy
+6,626
New +$17.8M 0.31% 74

Other funds holding APLM

ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
PIA
Powell Investment Advisors Miami, Florida $317M AUM 26.57% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
B
Bensler Bellevue, Washington $1.13B AUM 38.91% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

OrbiMed's APLM Position: Q3 2024 in Review

OrbiMed sold out of Apollomics (APLM) in Q3 2024, closing a stake of 85,655 shares — an estimated $1.81M sold.

OrbiMed first reported a position in APLM in Q1 2023 and held it in 6 quarters. The position peaked at $67.4M in Q3 2023. 11 funds tracked by Wall St. Rank hold APLM as of Q3 2024.

  • OrbiMed reported no remaining Apollomics position as of Q3 2024 after selling out during the quarter.
  • OrbiMed sold 85,655 Apollomics shares in Q3 2024, an estimated $1.81M.
  • OrbiMed first reported a position in Apollomics in Q1 2023 and held it in 6 quarters.
  • OrbiMed's Apollomics position peaked at $67.4M in Q3 2023.
  • 11 funds tracked by Wall St. Rank held Apollomics as of Q3 2024.

Based on OrbiMed's 13F filing for Q3 2024, filed 14 Nov 2024.